177 related articles for article (PubMed ID: 28797730)
21. Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays.
Caì Y; Iwasaki M; Beitzel BF; Yú S; Postnikova EN; Cubitt B; DeWald LE; Radoshitzky SR; Bollinger L; Jahrling PB; Palacios GF; de la Torre JC; Kuhn JH
Viruses; 2018 Nov; 10(11):. PubMed ID: 30463334
[TBL] [Abstract][Full Text] [Related]
22. Identification of protective Lassa virus epitopes that are restricted by HLA-A2.
Botten J; Alexander J; Pasquetto V; Sidney J; Barrowman P; Ting J; Peters B; Southwood S; Stewart B; Rodriguez-Carreno MP; Mothe B; Whitton JL; Sette A; Buchmeier MJ
J Virol; 2006 Sep; 80(17):8351-61. PubMed ID: 16912286
[TBL] [Abstract][Full Text] [Related]
23. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein.
Galan-Navarro C; Rincon-Restrepo M; Zimmer G; Ollmann Saphire E; Hubbell JA; Hirosue S; Swartz MA; Kunz S
Virology; 2017 Dec; 512():161-171. PubMed ID: 28963882
[TBL] [Abstract][Full Text] [Related]
24. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever.
Cross RW; Woolsey C; Prasad AN; Borisevich V; Agans KN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Geisbert TW
Cell Rep; 2022 Jul; 40(3):111094. PubMed ID: 35858566
[TBL] [Abstract][Full Text] [Related]
25. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing Antibodies against Lassa Virus Lineage I.
Buck TK; Enriquez AS; Schendel SL; Zandonatti MA; Harkins SS; Li H; Moon-Walker A; Robinson JE; Branco LM; Garry RF; Saphire EO; Hastie KM
mBio; 2022 Aug; 13(4):e0127822. PubMed ID: 35730904
[TBL] [Abstract][Full Text] [Related]
27. An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.
Li D; Chen T; Hu Y; Zhou Y; Liu Q; Zhou D; Jin X; Huang Z
J Virol; 2016 Oct; 90(19):8720-8. PubMed ID: 27440895
[TBL] [Abstract][Full Text] [Related]
28. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albariño CG
Antiviral Res; 2016 Dec; 136():9-18. PubMed ID: 27771389
[TBL] [Abstract][Full Text] [Related]
29. Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus.
Lee AM; Cruite J; Welch MJ; Sullivan B; Oldstone MB
Virology; 2013 Aug; 442(2):114-21. PubMed ID: 23684417
[TBL] [Abstract][Full Text] [Related]
30. The search for animal models for Lassa fever vaccine development.
Lukashevich IS
Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740
[TBL] [Abstract][Full Text] [Related]
31. Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study.
Davies J; Lokuge K; Glass K
Vaccine; 2019 Jun; 37(26):3451-3456. PubMed ID: 31088745
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.
Müller H; Fehling SK; Dorna J; Urbanowicz RA; Oestereich L; Krebs Y; Kolesnikova L; Schauflinger M; Krähling V; Magassouba N; Fichet-Calvet E; Ball JK; Kaufmann A; Bauer S; Becker S; von Messling V; Strecker T
NPJ Vaccines; 2020; 5(1):71. PubMed ID: 32802410
[No Abstract] [Full Text] [Related]
33. Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.
Enriquez AS; Buck TK; Li H; Norris MJ; Moon-Walker A; Zandonatti MA; Harkins SS; Robinson JE; Branco LM; Garry RF; Saphire EO; Hastie KM
Cell Rep; 2022 May; 39(8):110841. PubMed ID: 35613585
[TBL] [Abstract][Full Text] [Related]
34. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.
Perrett HR; Brouwer PJM; Hurtado J; Newby ML; Liu L; Müller-Kräuter H; Müller Aguirre S; Burger JA; Bouhuijs JH; Gibson G; Messmer T; Schieffelin JS; Antanasijevic A; Boons GJ; Strecker T; Crispin M; Sanders RW; Briney B; Ward AB
Cell Rep; 2023 May; 42(5):112524. PubMed ID: 37209096
[TBL] [Abstract][Full Text] [Related]
35. Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection.
Oestereich L; Müller-Kräuter H; Pallasch E; Strecker T
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515124
[TBL] [Abstract][Full Text] [Related]
36. Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments.
Hulseberg CE; Fénéant L; Szymańska KM; White JM
mBio; 2018 Jan; 9(1):. PubMed ID: 29295909
[TBL] [Abstract][Full Text] [Related]
37. Lassa virus diversity and feasibility for universal prophylactic vaccine.
Lukashevich IS; Paessler S; de la Torre JC
F1000Res; 2019; 8():. PubMed ID: 30774934
[TBL] [Abstract][Full Text] [Related]
38. Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities.
Nie J; Liu L; Wang Q; Chen R; Ning T; Liu Q; Huang W; Wang Y
Emerg Microbes Infect; 2019; 8(1):272-281. PubMed ID: 30866781
[TBL] [Abstract][Full Text] [Related]
39. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
[TBL] [Abstract][Full Text] [Related]
40. Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding.
Illick MM; Branco LM; Fair JN; Illick KA; Matschiner A; Schoepp R; Garry RF; Guttieri MC
Virol J; 2008 Dec; 5():161. PubMed ID: 19105844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
